系统性红斑狼疮的自体干细胞移植：17例患者7年随访的疗效与安全性报告
Autologous stem cell transplantation for systemic lupus erythematosus: report of efficacy and safety at 7 years of follow-up in 17 patients.
作者信息
Song X-N, Lv H-Y, Sun L-X, Meng J-B, Wang J-K, Zhang J-Q, Chang Y-J
机构信息
Department of Hematology, Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, China.
出版信息
Transplant Proc. 2011 Jun;43(5):1924-7. doi: 10.1016/j.transproceed.2011.03.039.
INTRODUCTION
We observed the efficacy and toxicity of autologous stem cell transplantation (auto-SCT) for patients with systemic lupus erythematosus (SLE).
METHODS
Seventeen patients with SLE were treated with auto-SCT. No prisoners were used in the study. Peripheral blood stem cells were mobilized with cyclophosphamide (Cy) and granulocyte colony-stimulating factor. After a conditioning regimen of Cy and antithymocyte globulin, we reinfused stem cells. The probabilities of overall survival (OS) and progression-free survival (PFS) were used to assess the efficacy and adverse experiences, to detect the toxicities of the treatment.
RESULTS
The median follow-up time was 89 months (range 33-110). Probabilities of 7-year OS and PFS were 82.4% ± 9.2% and 64.7% ± 11.6%, respectively. The principal adverse events included allergy, infection, elevation of liver enzymes, bone pain, and heart failure. Two patients died due to severe pneumonia and heart failure at 33 and 64 months after transplantation, respectively.
CONCLUSIONS
Our 7-year follow-up results suggested that auto-SCT seemed beneficial for SLE patients.
引言
我们观察了自体干细胞移植（auto-SCT）治疗系统性红斑狼疮（SLE）患者的疗效和毒性。
方法
17例SLE患者接受了auto-SCT治疗。本研究未使用囚犯。采用环磷酰胺（Cy）和粒细胞集落刺激因子动员外周血干细胞。在进行Cy和抗胸腺细胞球蛋白预处理方案后，我们回输了干细胞。采用总生存率（OS）和无进展生存率（PFS）来评估疗效和不良经历，以检测治疗的毒性。
结果
中位随访时间为89个月（范围33 - 110个月）。7年OS率和PFS率分别为82.4%±9.2%和64.7%±11.6%。主要不良事件包括过敏、感染、肝酶升高、骨痛和心力衰竭。两名患者分别在移植后33个月和64个月因严重肺炎和心力衰竭死亡。
结论
我们7年的随访结果表明，auto-SCT似乎对SLE患者有益。
Zotero 插件